Trial document



drksid header

  DRKS00024668

Trial Description

start of 1:1-Block title

Title

Observational study to assess the SARS-CoV-2 specific immune response in kidney transplant recipients (COVID-19 related immune response)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Kidney transplant recipients are due to their medical need of immunosuppressive medication following transplantation as well as their often coexisting comorbidities, especially regarding the cardiovascular system, at high risk for a severe course of COVID-19 disease when compared to healthy individuals. On the other hand the fast development of SARS-CoV_2 specific vaccines give hope to fighting the current COVID-19 pandemic.

It is already known, that the antibody-mediated as well as cell-mediated immune response of immunocompromised patients to other viral diseases or vaccinations against viral diseases, such as Influenza or Hepatitis B, is impaired. Current research suggests that immunocompromised patients develop an adequate immune response to an infection with SARS-CoV-2. It is however not known, how the immune response to SARS-CoV-2 specific vaccination is.

In this study the immune response following COVID-19 diesease or SARS-CoV-2 infection in renal transplant recipients will be assessed. Healthy participants without chronic kidney disease will serve as control.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

At present, two mRNA vaccines are approved for vaccination against COVID-19: BNT162b2/Comirnaty (BioNTech/Pfizer) and mRNA-1273/COVID-19-vaccine (Moderna). At the end of january another, vector-based vaccine, AZD1222 (AstraZeneca) further got approval. All three vaccines demonstrated sufficient efficacy in preventing COVID-19 disease and led to significant reduction in severe courses of COVID-19 disease in vaccinated participants. As the authorisation studies however only included healthy individuals, little is known about vaccine induced immunity in immunocompromised patients.
Studies regarding influenza vaccination in renal transplant recipients showed significant impaired vaccine-induced immunity due to immunosuppressive medication. In a prospective vaccination study regarding vaccination against Hepatitis A in immunisuppressed liver- and kidney transplant recipients a fast humoral response to vaccination could be demonstrated, however, antibody titers decreased faster than in healthy control participants.

Recent studies could show an adequate antibody-mediated and cellular response following SARS-CoV-2 infection, even in immunocompromised patients. However, little is known on how long this immunity after COVID-19 infection lasts.

In this observational trial the humoral and cellular response to SARS-CoV-2 antigen exposure, either by infection of by vaccination will be evaluated in renal transplant recipients. Participants without chronic kidney disease will serve as healthy controls.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

Data will not be shared due to monocentric observational character of this study.

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00024668
  •   2021/03/23
  •   [---]*
  •   yes
  •   Approved
  •   S-201/2021, Ethik-Kommission I der Medizinischen Fakultät Heidelberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Z94.0 -  Kidney transplant status
  •   U07.1 -  Emergency use of U07.1
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Investigation of SARS-CoV-2 specific immunity in Kidney transplant recipients or combined kidney-pancreas transplant recipients (de novo or re-transplanted)
  •   Investigation of SARS-CoV-2 specific immunity in Patients without chronic kidney disease (>CKD Stadium 3b (GFR >45 ml/min/1.73m2))
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Diagnostic
  •   Parallel
  •   IV
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

SARS-CoV-2 specific immunity after SARS-CoV-2 antigen exposure
1) antibody-mediated immune response 28-42 days (=d) after SARS-CoV-2 antigen exposure (infection OR vaccinatino). Quantification of SARS-CoV-2 specific antibodies (IgG against nucleocapsid-antigen; IgG and IgM against receptor-binding-domain of S1-antigen)
2) cellular immunity 28-42d after SARS-CoV-2 antigen exposure (infectino OR exposure). Evaluation of SARS-CoV-2 antigen-specific t-cellular response by FACS-analysis

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

SARS-CoV-2 specific immunity after SARS-CoV-2 antigen exposure, maximum of 10 measurements per patient, depending on availability
1) antibody-mediated immune response, same as in primary outcome measures, at further time points (14-21d, 42-56d, 56-70d, 84-94d, 112-126d, 140-154d, 168-182d, 196-210d) after SARS-CoV-2 antigen exposure
2) Evaluation of cellular immunity, same as in primary outcome measures, at further time points (14-21d, 42-56d, 56-70d, 84-94d, 112-126d, 140-154d, 168-182d, 196-210d) after SARS-CoV-2 antigen exposure

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2021/03/23
  •   150
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   16   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Arm 1: Kidney transplant recipients (de-novo or re-transplanted); kidney-pancreas transplant recipients (de-novo or re-transplanted); no active malignancy; >16 years of age.
Arm 2: patients without chronic kidney disease (>CKD Stadium 3b (GFR >45 ml/min/1.73m2)); no current immunosuppressive medication; no active malignancy; >16 years of age.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

No informed consent available; not meeting above mentioned eligibility criteria.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Nierenzentrum Heidelberg
    • Im Neuenheimer Feld 162
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   49 (0)6221/91120
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Nierenzentrum Heidelberg, Universitätsklinikum Heidelberg
    • Ms.  Dr. med.  Louise  Benning 
    • Im Neuenheimer Feld 162
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address scientific-contact
    • Nierenzentrum Heidelberg
    • Mr.  Dr. med.  Claudius  Speer 
    • Im Neuenheimer Feld 162
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Nierenzentrum Heidelberg, Universitätsklinikum Heidelberg
    • Ms.  Dr. med.  Louise  Benning 
    • Im Neuenheimer Feld 162
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
  • start of 1:1-Block address public-contact
    • Nierenzentrum Heidelberg
    • Mr.  Dr. med.  Claudius  Speer 
    • Im Neuenheimer Feld 162
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Nierenzentrum Heidelberg
    • Im Neuenheimer Feld 162
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   49 (0)6221/91120
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.